Last updated: April 25, 2026
Which company supplies RITALIN LA in the US?
RITALIN LA is marketed in the US by Novartis Pharmaceuticals Corporation (brand owner and marketing authorization holder for the US product line). The US label identifies the manufacturer for the dosage form and packaging chain through the product’s “manufactured for”/“distributed by” sections.
Market authorization label (US):
- Brand/Marketing holder: Novartis Pharmaceuticals Corporation
- Drug substance: methylphenidate hydrochloride (extended-release formulation)
- Dosage form: capsule, extended release (bead technology)
What are the typical supplier roles for RITALIN LA?
For an extended-release methylphenidate product, supplier relationships usually fall into four buckets:
- Drug substance (API) supplier for methylphenidate hydrochloride
- Dosage form manufacturer that produces and fills the extended-release capsule (and manufactures the bead/particle system)
- Packaging and labeling contractor (bottles/blisters, cartons, NDC label application)
- Finished-goods distributor (often the marketing authorization holder’s distribution network)
Public sources that name specific contract manufacturers and API suppliers tend to appear in:
- US FDA drug label “manufactured for/distributed by” text
- Regulatory facility listings (for finished product manufacturing sites)
- Patent assignees and manufacturing process disclosures tied to the product’s controlled-release technology
What is documented about RITALIN LA’s manufacturing chain?
Public-facing references for RITALIN LA consistently identify Novartis as the brand owner/US marketing entity. The detailed list of named contract manufacturers for each RITALIN LA strength can vary by production site and time. The most reliable, label-anchored proof is the US package insert text that binds the product to its listed manufacturer/distributor language.
RITALIN LA label anchor (US):
- Novartis Pharmaceuticals Corporation is listed as the company associated with the product’s distribution/marketing on the US label (manufacturer/distributor statements in the prescribing information).
RITALIN LA supplier map (what can be stated from regulatory-label level facts)
Below is the supplier-role structure that can be stated with certainty from US-label level sourcing:
| Supplier role |
Who |
What the role covers |
Evidence level |
| Marketing authorization holder / US supplier of record |
Novartis Pharmaceuticals Corporation |
Brand supply chain for the marketed US product |
US label distributor/marketing holder text |
| API supplier (methylphenidate HCl) |
Not uniquely identified in general public label summaries |
Methylphenidate hydrochloride used in the dosage form |
Not consistently named at label level in public summaries |
| Dosage form manufacturer (capsule beads/ER system) |
Not uniquely identified in a single public “supplier list” view |
Production of extended-release capsule components and filling |
Requires strength-specific label manufacturer language and/or facility citations |
| Packaging/labeling/distribution |
Tied to Novartis’ distribution network and/or contract packers |
Cartoning/bottling, NDC labeling, logistics |
Label distribution statements |
What sources typically name the contract manufacturing site?
For controlled-release brands like RITALIN LA, the public manufacturer name usually comes from the latest FDA label revision, where the label states “manufactured for” or “distributed by” alongside a location. That location often indicates the finished dose manufacturing site or a site responsible for commercial release.
Patent filings related to:
- methylphenidate controlled release bead technology
- sustained-release dosing designs
- formulation processes
can name assignees and, in some cases, companies tied to formulation development, though this does not always translate into today’s commercial manufacturing suppliers.
Actionable diligence checklist for supplier identification (label-to-site path)
To identify RITALIN LA’s actual suppliers with evidentiary linkage, the standard approach is to map:
- Current US label revision to the label’s “manufactured for/distributed by” language (company + address)
- Strength-specific label sections (some labels list different manufacturing sites for different strengths)
- Facility name mapping against FDA facility listings for the finished dose category
- Procurement side validation through incoming COAs and supplier master data (where required)
Key supplier conclusions that hold at the business-relevant level
- Novartis is the identified US marketing/distribution entity for RITALIN LA in public product labeling.
- The exact API supplier and specific contract manufacturing site names are not reliably enumerated in a single consolidated public “supplier list” and must be derived from label manufacturing/distribution statements and facility records for the relevant strength and label revision.
Key Takeaways
- Novartis Pharmaceuticals Corporation is the US marketing/distribution supplier of record for RITALIN LA based on US label statements.
- RITALIN LA supply chain analysis splits into API, finished-dose/ER capsule manufacturing, and packaging/distribution roles.
- The most provable supplier naming comes from the current US prescribing information “manufactured for/distributed by” text tied to each label revision and strength.
FAQs
Who is the supplier of RITALIN LA in the US?
Novartis Pharmaceuticals Corporation is the US marketing/distribution entity for RITALIN LA based on the US product label.
Are RITALIN LA API suppliers named on the US label?
Often not in a consolidated way on label summaries; API sourcing typically requires label manufacturing/distribution language and/or facility/patent-linked records.
Do the manufacturing suppliers differ by strength or label revision?
Yes. Finished-dose manufacturing and release sites can change by strength and by label revision, so supplier identification should be tied to the specific label version.
What types of suppliers are involved beyond the brand owner?
The supply chain typically includes the API supplier, the finished-dose manufacturer for the extended-release capsule/bead system, and packaging/labeling contractors tied into distribution.
What is the fastest path to confirm contract manufacturers for procurement diligence?
Use the current US label’s “manufactured for/distributed by” section and map the stated site to FDA facility records, then validate via COAs and supplier master data.
References
- Novartis Pharmaceuticals Corporation. RITALIN LA (methylphenidate hydrochloride) prescribing information / US label. FDA label and package insert.
